The therapy lengthened telomeres and improved immune function in people with telomere biology disorder, showing promise for treating bone marrow failure safely.
The team at DropGenie uses digital microfluidics to perform gene editing screens on small numbers of patient cells, accelerating the discovery of new drugs.
As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
Researchers discovered an immunological connection between the eye and the brain that could lead to new therapeutics for central nervous system diseases.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.